Samsung Biologics (KRX:207940) secured a contract manufacturing organization (CMO) contract worth 119.1 billion won from an undisclosed Asian pharmaceutical company.
The contract is valid till December 2028, the South Korean firm said in a Wednesday corporate disclosure.